Pharmaceutical products include an FDA approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial. The company operates in specialized niches within healthcare, personal care, and cosmetics with differentiated hydrogel technology as its core competitive advantage.
Cyborg Score Rationale
United Guardian is a small-cap specialty chemical manufacturer with micro-cap scale (~$28-32M market cap as of June 2026) and limited analyst coverage. While the company has niche competitive advantages in hydrogel formulations and a diversified product portfolio across pharma, cosmetics, and wellness segments, its tiny scale, minimal revenue visibility, and execution risk in multiple markets create meaningful valuation and growth challenges.
Top Insights
Diversified across four product categories (cosmetic ingredients, pharmaceuticals, medical lubricants, sexual wellness) reducing single-market concentration risk
Core Lubrajel hydrogel platform serves multiple high-margin application areas including prescription pharmaceuticals and premium personal care
Micro-cap public company with minimal institutional coverage and trading volume, creating liquidity and information asymmetry risk
Small employee base (~22-25 full-time staff) limits scaling capacity and may constrain growth ambitions across multiple markets
Named Competitors
Performance Materials — Diversified chemical company with cosmetic and medical ingredient portfolios
Specialty Chemicals — Global specialty chemical manufacturer competing in personal care and pharmaceuticals
Advanced Polymers — Diversified chemical producer with medical device and cosmetic ingredient offerings
Open the full interactive United-Guardian, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.